key: cord-0951726-nmefqhfn authors: Zomalheto, Zavier; Assogba, Calixte; Dossou-yovo, Hilaire title: Impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection and disease -2019 (COVID-19) on the quality of life of rheumatoid arthritis patients in Benin date: 2020-07-04 journal: nan DOI: 10.1016/j.ejr.2020.07.001 sha: 49e09319861e69262269b5273e50972a861407d4 doc_id: 951726 cord_uid: nmefqhfn Abstract Aim of the work: To study the impact on the quality of life (QoL) of rheumatoid arthritis (RA) patients following up in a university hospital in Benin during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) disease 2019 (COVID-19) pandemic. Patients and methods The QoL of 68 RA patients was assessed using Medical Outcome Study Short Form 36 (MOS-SF36) scale across the physical (PCS) and mental (MCS) components scores. The disease activity score (DAS28) was considered. Patients accepting to participate and having a mean of communication via social network, in particular WhatsApp were included. Results The mean age of the patients was 49.9±12.1 years (11-83 years) and were 65 females and 3 males. The mean DAS-28 at the start of the restriction measures was 3.4±1.5, the mean PCS and MCS were 71.1±20.3 and 67.1±16.02 respectively and became 4.7±2.04, 38.1±4.96 and 36.8±3.8 respectively. After 2 months, none of the RA patients presented with classic symptoms of COVID-19 infection. 8 patients were screened by Rapid Diagnostic Test and Reverse Transcription‐Polymerase Chain Reaction. Only 1 case was positive but asymptomatic. All patients had altered QoL according to MOS-SF36. Factors associated with this deterioration were stress related to SARS-CoV2 isolation (p=0.001), stress of having an activity flare-up (p=0.001), fear of being stigmatized (p=0.009). The economic factors were signficantly associated with temporary unemployment, decrease in monthly income, and drug discontinuation (p=0.001, p=0.002 and p=0.046 respectively). Conclusion The impact of the SARS-CoV2 pandemic is negative on the QoL of RA patients and many factors were contributing. Current pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite drastic containment measures, the COVID-19 outbreak has taken lives of more than 330,000 people worldwide, with the number of those contracting the virus surpassing 500,000,000 (as of . Since WHO declared the SARS-cov2 pandemic, psychosis has been prevalent in all countries [1] . Environmental factors such as air pollution and smoking, as well as co-morbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory disease) are likely to increase the severity of COVID-19 [2] . Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals [3] . The presence of joint manifestations as symptoms of the disease is of great concern to rheumatologists and to patients suffering from chronic inflammatory rheumatism. These patients, as the majority of patients, are visiting fewer and fewer hospitals for fear of being infected. Teleconsultation and other forms of consultation have emerged in several countries. Patients suffering from chronic inflammatory rheumatism have received a lot of attention in recent weeks because of the possible beneficial effects of anti-rheumatic treatments in the fight against the virus [4] . However, the state of mind of the patients followed up in rheumatology during this crisis has not been addressed. In Africa, the epidemic is progressing at a very slow pace where the number of cases of COVID-19 remains far lower than in Western countries. In a north African country, Egypt, rheumatology patients visits were spaced, followed-up by phone and were instructed to remain on their latest regimens unless there is evidence of an active infection. In patients with stable disease or in remission, a slow taper of immune suppressants was considered on a caseby-case basis. Priority was for urgent and infection-related appointments [5] . In Benin, the alleged first case of COVID-19 was diagnosed on11 march 2020 in the town of Cotonou. Among the 10 million inhabitants (including 0.8% of patients suffering from rheumatoid arthritis according to hospital surveys), the current number of cases diagnosed in May is 130 [6, 7] . Despite the attempt to limit the outbreak to the defined "red zone", by quarantining all citizens and denying entry or departure from the area similar cases were diagnosed in other cities without evident epidemiological correlation. These measures are not without socio-economic and psychological consequences for the population in general and for the rheumatoid arthritis (RA) patients in particular. Even before the pandemic, sleep disturbances, depression and lonliness were frequently reported in RA patients and were associated with worse health outcomes [8] . Moreover, viral infections were reported in rheumatic diseases [9, 10] and association to RA had a definite impact [11, 12] . The aim of this work was to study the quality of life (QoL) of RA patients followed in rheumatology units in Cotonou (Benin) during the SARS-CoV2 pandemic. This is a descriptive and analytical cross-sectional study for the period from May 1 to May 31, 2020, of 68 RA patients who followed up in the rheumatology department of the National Hospital University Hubert Koutoukou Maga for at least 1 year and were diagnosed according to the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 criteria [13] . Patients accepting to participate and having a mean of communication via social network, in particular WhatsApp were included. Patients with <1 year disease duration and those who cannot fill in the questionnaire data via WhatsApp or who are unable to travel to the hospital were excluded from the study. Informed consent was obtained from all patients after a full explanation of the study was provided. The study was approved by the Faculty of Health Sciences ethics committee. The QoL of patients was assessed using the Medical Outcome Study Short Form 36 (MOS-SF36) scale through Physical Components Score (PCS) and Mental Components Score (MCS) [14] . Data were collected using a survey form filled out directly in consultation for patients who were able to visit the hospital during the study period or via a network Statistical analysis: It was carried out by Epi data 3.1 and SPSS statistics (18.0; IBM Corp., USA). Values were presented as means and standard deviations, ranges or frequencies and percentages. Variables were compared using the Mann-Whitney U-test and categorical data using Fisher's exact test. p<0.05 were considered significant. Sixty-eight RA patients participated in the study. They were 65 females and 3 males (F:M 21.7:1). The mean age of the patients was 49.9±12.1 years (11-83 years). The mean DAS-28 was 3.4±1.5 (1.2-6.8). The general characteristics and the evolution of the QoL of the patients before and after the restriction measures are grouped in Table 1 . Regarding the data on SARS-CoV2 infection (Table 2) These factors are summarized in Tables 3 and 4 . Africa, despite having the world's greatest infectious disease burden, has a weak epidemiological surveillance system. Even in Europe, with its more advanced information systems, the official data on COVID-19 are controversial because of poor standardisation [15] . The COVID-19 pandemic poses a challenge not only for sub-Saharan African countries but also for those with well functioning health systems. The responsibility now for African scientists is to join forces and fight at local and regional levels to ensure the slow down and eventual halt of the spread of COVID-19 [16] . To date, the burden and outcomes associated with COVID-19 have varied substantially across the African continent. Specifically, 8 of the 54 African countries-South Africa, Egypt, Nigeria, Algeria, Ghana, Morocco, Cameroon, and Sudan-account for two thirds of all known COVID-19 cases [17] . The COVID-19 pandemic has come with many challenges for rheumatology healthcare providers and patients alike with a direct burden on health systems and a significant impact in the care and follow-up of patients with rheumatic and musculoskeletal diseases [18] . Furthermore, changes in treatment adherence behaviour in rheumatic diseases during COVID-19 pandemic has been addressed [19] . However, COVID-19 incidence in patients with rheumatic autoimmune diseases seemed to be similar the general population in Northeast Italy [20] . An increased psychological distress has been proposed in patients with rheumatic diseases during the COVID-19 outbreak and their psychiatric symptoms were of considerable clinical concern, similar to the frequency in rheumatology staff members but significantly lower than that observed among hospital workers [21] . Moreover, the pattern of proinflammatory cytokines induced in COVID-19 has similarities to those targeted in the treatment of RA [22] . Patients with RD are susceptible to COVID-19. Various DMARDs or biologics may affect the viral disease course differently [23] . Concerns regarding the risk of COVID-19 among patients on anti-rheumatic drugs are common [24] . Patients with RA have increased risk of infection and are treated with medications that may increase this risk yet are also hypothesized to help treat COVID-19. In Benin, one of less developped countries, most of the patients suffering from RA are treated with, methotrexate alone or associated with salazopyrine or hydroxychloroquine. No biologic medication is taken because of the cost. This explains why two thirds of the patients were moderately or highly active requiring prednisone. This therapeutic difficulty linked to the cost of treatment is widely observed in most developing countries [25] [26] [27] . Insufficiently controlled rheumatology patients are at a reduced hospital attendance rate. This rate greatly weakened during the period of the restriction measures with only 2 patients present at the hospital during the 2 months of restriction. The main reason given was the fear of being infected with SARS-CoV2. This patient avoidance experience was recently mentioned by Michaud et al. [28] . On the other hand, of the 530 COVID-19 questionnaire respondents, 471 answered questions about changes in their rheumatology care. Of these, 42% reported some change in the previous two weeks; half of them cancelled or postponed appointments, 24% switched to teleconference, 14% reported changes to their medication list or dose, 11% reported physician directed changes to their medication list or dose, 10% were unable to obtain their medication, and 4% were unable to reach their rheumatology office. This statement is updated on an ongoing basis, in response to evolving events and common media queries Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets Clinical characteristics of coronavirus disease 2019 in China Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS CoV-2 infection Egypt's groundwork blessing during the COVID-19 pandemic curse: Rheumatologic experience Rheumatism disease in the African environment in the 21st century. Profile of 9992 West African patients WHO. Coronavirus-covid-19 Rheumatology in Egypt: back to the future Low detection of hepatitis B and occult hepatitis B infection in patients with rheumatic diseases Hepatitis C virus infection among patients admitted to a rheumatology ward in northern Cyprus Impact of hepatitis C virus infection on disease activity, functional status and ultrasonography findings in Egyptian rheumatoid arthritis patients Elevated Cytomegalovirus and Epstein-Barr virus burden in rheumatoid arthritis: A true pathogenic role or just a coincidence Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Medical outcomes study short form 36 : testing and cross-validating a secondorder factorial structure for health system employees COVID-19 in Africa COVID-19 in Africa: between hope and reality COVID-19 Across Africa: Epidemiologic Heterogeneity and Necessity of Contextually Relevant Transmission Models and Intervention Strategies Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A crosssectional study on 916 patients The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey COVID-19 revisiting inflammatory pathways of arthritis COVID-19 in rheumatic disease patients on immunosuppressive agents Perspectives of patients with rheumatic diseases in the early phase of COVID-19 Profile of rheumatoid arthritis in rheumatology consultation in Lomé Rheumatoid arthritis in Burkina Faso: clinical and serological profiles Experiences of Patients with Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs The authors have declared no conflict of interest.Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.